349 related articles for article (PubMed ID: 28892086)
21. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
Bashir Q; Khan H; Thall PF; Liu P; Shah N; Kebriaei P; Parmar S; Oran B; Ciurea S; Nieto Y; Jones R; Hosing CM; Popat UR; Dinh YT; Rondon G; Orlowski RZ; Shah JJ; De Lima M; Shpall E; Champlin R; Giralt S; Qazilbash MH
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1453-8. PubMed ID: 23872222
[TBL] [Abstract][Full Text] [Related]
22. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Bashir Q; Khan H; Orlowski RZ; Amjad AI; Shah N; Parmar S; Wei W; Rondon G; Weber DM; Wang M; Thomas SK; Shah JJ; Qureshi SR; Dinh YT; Popat U; Anderlini P; Hosing C; Giralt S; Champlin RE; Qazilbash MH
Am J Hematol; 2012 Mar; 87(3):272-6. PubMed ID: 22231283
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study.
Sandoval-Sus JD; Faramand R; Chavez J; Puri S; Parra P; Sokol L; Kharfan-Dabaja MA; Shah B; Ayala E
Leuk Lymphoma; 2019 Feb; 60(2):309-316. PubMed ID: 29963932
[TBL] [Abstract][Full Text] [Related]
25. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.
Rosiñol L; Jiménez R; Rovira M; Martínez C; Fernández-Avilés F; Marín P; Suárez-Lledó M; Gutiérrez-García G; Fernández de Larrea C; Carreras E; Urbano-Ispizua A; Bladé J
Bone Marrow Transplant; 2015 May; 50(5):658-62. PubMed ID: 25621810
[TBL] [Abstract][Full Text] [Related]
27. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
28. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
29. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.
Patriarca F; Bruno B; Einsele H; Spina F; Giaccone L; Montefusco V; Isola M; Nozzoli C; Nozza A; Morabito F; Corradini P; Fanin R
Biol Blood Marrow Transplant; 2018 Feb; 24(2):406-409. PubMed ID: 29032267
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract][Full Text] [Related]
32. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
33. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
34. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
35. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma.
Kawamura K; Tsukada N; Kanda Y; Ikeda T; Yoshida A; Ueda Y; Ishida T; Suzuki K; Murakami H
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1392-1398. PubMed ID: 29555314
[TBL] [Abstract][Full Text] [Related]
36. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.
Greil C; Engelhardt M; Ihorst G; Schoeller K; Bertz H; Marks R; Zeiser R; Duyster J; Einsele H; Finke J; Wäsch R
Haematologica; 2019 Feb; 104(2):370-379. PubMed ID: 30237266
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
[TBL] [Abstract][Full Text] [Related]
39. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S
Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
